Structural Studies of HNA Substrate Specificity in Mutants of an Archaeal DNA Polymerase Obtained by Directed Evolution.

Archaeal DNA polymerases from the B-family (polB) have found essential applications in biotechnology. In addition, some of their variants can accept a wide range of modified nucleotides or xenobiotic nucleotides, such as 1,5-anhydrohexitol nucleic acid (HNA), which has the unique ability to selectively cross-pair with DNA and RNA. This capacity is essential to allow the transmission of information between different chemistries of nucleic acid molecules. Variants of the archaeal polymerase from Thermococcus gorgonarius, TgoT, that can either generate HNA from DNA (TgoT_6G12) or DNA from HNA (TgoT_RT521) have been previously identified. To understand how DNA and HNA are recognized and selected by these two laboratory-evolved polymerases, we report six X-ray structures of these variants, as well as an in silico model of a ternary complex with HNA. Structural comparisons of the apo form of TgoT_6G12 together with its binary and ternary complexes with a DNA duplex highlight an ensemble of interactions and conformational changes required to promote DNA or HNA synthesis. MD simulations of the ternary complex suggest that the HNA-DNA hybrid duplex remains stable in the A-DNA helical form and help explain the presence of mutations in regions that would normally not be in contact with the DNA if it were not in the A-helical form. One complex with two incorporated HNA nucleotides is surprisingly found in a one nucleotide-backtracked form, which is new for a DNA polymerase. This information can be used for engineering a new generation of more efficient HNA polymerase variants

Defining the causes of sporadic Parkinson's disease in the global Parkinson's genetics program (GP2)

The Global Parkinson’s Genetics Program (GP2) will genotype over 150,000 participants from around the world, and integrate genetic and clinical data for use in large-scale analyses to dramatically expand our understanding of the genetic architecture of PD. This report details the workflow for cohort integration into the complex arm of GP2, and together with our outline of the monogenic hub in a companion paper, provides a generalizable blueprint for establishing large scale collaborative research consortia

Multi-ancestry genome-wide association meta-analysis of Parkinson?s disease

Although over 90 independent risk variants have been identified for Parkinson’s disease using genome-wide association studies, most studies have been performed in just one population at a time. Here we performed a large-scale multi-ancestry meta-analysis of Parkinson’s disease with 49,049 cases, 18,785 proxy cases and 2,458,063 controls including individuals of European, East Asian, Latin American and African ancestry. In a meta-analysis, we identified 78 independent genome-wide significant loci, including 12 potentially novel loci (MTF2, PIK3CA, ADD1, SYBU, IRS2, USP8, PIGL, FASN, MYLK2, USP25, EP300 and PPP6R2) and fine-mapped 6 putative causal variants at 6 known PD loci. By combining our results with publicly available eQTL data, we identified 25 putative risk genes in these novel loci whose expression is associated with PD risk. This work lays the groundwork for future efforts aimed at identifying PD loci in non-European populations

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Background Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. Methods RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report on the comparison of short-course versus long-course ADT. Key eligibility criteria were indication for radiotherapy after previous radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to add 6 months of ADT (short-course ADT) or 24 months of ADT (long-course ADT) to radiotherapy, using subcutaneous gonadotrophin-releasing hormone analogue (monthly in the short-course ADT group and 3-monthly in the long-course ADT group), daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as metastasis arising from prostate cancer or death from any cause. The comparison had more than 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 75% to 81% (hazard ratio [HR] 0·72). Standard time-to-event analyses were used. Analyses followed intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov , NCT00541047 . Findings Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60–69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 8·9 years (7·0–10·0), 313 metastasis-free survival events were reported overall (174 in the short-course ADT group and 139 in the long-course ADT group; HR 0·773 [95% CI 0·612–0·975]; p=0·029). 10-year metastasis-free survival was 71·9% (95% CI 67·6–75·7) in the short-course ADT group and 78·1% (74·2–81·5) in the long-course ADT group. Toxicity of grade 3 or higher was reported for 105 (14%) of 753 participants in the short-course ADT group and 142 (19%) of 757 participants in the long-course ADT group (p=0·025), with no treatment-related deaths. Interpretation Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy. Funding Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Une représentation en trois dimensions de l'interface entre l'enveloppe nucléaire et la chromatine

The nucleus is an organelle characteristic of eukaryotic cells and its mechanical properties play an essential role in the behavior of the cell, in particular its motility, polarity and survival. It is surrounded by an envelope comprising an inner membrane and an outer membrane, as well as a large number of proteins. These proteins are either anchored at the nuclear membrane, as emerin, or form a filament meshwork lining the inner nuclear membrane, as lamins. My thesis objectives were to understand molecular mechanisms deficient in two types of genetic diseases caused by mutations in inner nuclear envelope proteins: Emery-Dreifuss muscular dystrophy, associated to mutations in emerin and A-type lamins, and progeroid syndromes caused by mutations in A-type lamins.First, we showed that the emerin protein self-assembles in vitro and in cells (Herrada, Samson et al., ACS Chem. Biol., 2015). I then studied the structure of emerin oligomers, determined the minimal protein fragment necessary for the formation of these oligomers, identify residues forming the structural core of these oligomers by solid-state NMR in collaboration with the group of Prof A. Lange (FMP Berlin), and described the impact of emerin mutations causing Emery-Dreifuss muscular dystrophy on emerin self-assembly (Samson et al., Biomol. NMR Assign. 2016, Samson et al., FEBS J. 2017). Then, I observed, mainly using solution-state NMR, that only the self-assembled form of emerin is able to interact with A-type lamin tail, and that mutants causing Emery-Dreifuss muscular dystrophy and unable to self-assemble are also defective in A-type lamin binding. I also obtained preliminary data showing that phosphorylation of emerin by the Src kinase, observed after a mechanical stress in purified nuclei, regulates the interaction between self-assembled emerin and A-type lamins.Finally, I showed that the monomeric form of emerin is able to form a ternary complex with A-type lamin tail through the chromatin-associated protein Barrier-to-Autointegration Factor (BAF). After having measured the protein-protein affinities within this complex, identified the minimal protein fragments involved in the complex and developed a robust protocol for purification of this complex, I was able to obtain crystals under several conditions. Subsequently, I solved the 3D structure of this complex by molecular replacement at a resolution of 2 Å. Finally, I showed that mutations in A-type lamins causing autosomal recessive progeroid syndromes impair interaction with BAF in vitro, and our collaborators at Univ. Paris Diderot, the team of Dr B. Buendia, showed that these same mutations induce a significant decrease in the proximity between lamin A and BAF in HeLa cells. An article with me as a first author is in preparation that reports all these new data.Le noyau est un organite caractéristique des cellules eucaryotes et les propriétés mécaniques de ce dernier jouent un rôle essentiel dans le comportement de la cellule, notamment sa motilité, sa polarité et sa survie. Le noyau est entouré par une enveloppe comprenant une membrane interne et une membrane externe, ainsi que de nombreuses protéines. Mes objectifs de thèse étaient de comprendre des mécanismes moléculaires déficients dans deux types de maladies génétiques causées par des mutations dans les lamines: la dystrophie musculaire d’Emery-Dreifuss et les syndromes de type progéroïde.Dans un premier temps, nous avons montré que l’émerine s’auto-associe in vitro et en cellules (Herrada et al. ACS Chem. Biol. 2015). J’ai ensuite étudié la structure des oligomères d’émerine, déterminé le fragment protéique minimal nécessaire à la formation de ces oligomères et décrit l’impact de mutations de l’émerine, causant une dystrophie musculaire d’Emery-Dreifuss, sur son auto-assemblage (Samson et al. Biomol NMR Assign. 2016 ; Samson et al. FEBS J. 2016). Puis, j’ai montré que seule cette forme auto-assemblée de l’émerine est capable d’interagir avec la lamine A et que la phosphorylation de l’émerine par la kinase Src, observée suite à un stress mécanique, régule cette interaction entre l’enveloppe nucléaire et le nucléosquelette.Pour finir, j’ai montré que la forme monomérique de l’émerine est capable de former un complexe ternaire avec BAF et la lamine A. Après avoir mesuré les affinités protéine-protéine au sein de ce complexe, identifié les fragments minimaux des différentes protéines permettant de former ce complexe et mis au point un protocole robuste de purification de ce complexe, j’ai pu obtenir des cristaux de ce complexe dans plusieurs conditions. Par la suite, nous avons pu résoudre la structure de ce complexe par remplacement moléculaire avec une résolution de 2 Å. Enfin, j'ai montré que les mutations dans les lamines de type A provoquant des syndromes de type progéroïde pouvaient altérer l'interaction avec BAF in vitro, et nos collaborateurs, l'équipe du Dr B. Buendia (Paris Diderot), ont montré que ces mêmes mutations induisaient une diminution significative de la proximité entre la lamine A et BAF dans les cellules HeLa. Un article, où je suis premier auteur, vient d’être soumis au journal NSMB

A three-dimensional view of the interface between nuclear envelope and chromatin

Le noyau est un organite caractéristique des cellules eucaryotes et les propriétés mécaniques de ce dernier jouent un rôle essentiel dans le comportement de la cellule, notamment sa motilité, sa polarité et sa survie. Le noyau est entouré par une enveloppe comprenant une membrane interne et une membrane externe, ainsi que de nombreuses protéines. Mes objectifs de thèse étaient de comprendre des mécanismes moléculaires déficients dans deux types de maladies génétiques causées par des mutations dans les lamines: la dystrophie musculaire d’Emery-Dreifuss et les syndromes de type progéroïde.Dans un premier temps, nous avons montré que l’émerine s’auto-associe in vitro et en cellules (Herrada et al. ACS Chem. Biol. 2015). J’ai ensuite étudié la structure des oligomères d’émerine, déterminé le fragment protéique minimal nécessaire à la formation de ces oligomères et décrit l’impact de mutations de l’émerine, causant une dystrophie musculaire d’Emery-Dreifuss, sur son auto-assemblage (Samson et al. Biomol NMR Assign. 2016 ; Samson et al. FEBS J. 2016). Puis, j’ai montré que seule cette forme auto-assemblée de l’émerine est capable d’interagir avec la lamine A et que la phosphorylation de l’émerine par la kinase Src, observée suite à un stress mécanique, régule cette interaction entre l’enveloppe nucléaire et le nucléosquelette.Pour finir, j’ai montré que la forme monomérique de l’émerine est capable de former un complexe ternaire avec BAF et la lamine A. Après avoir mesuré les affinités protéine-protéine au sein de ce complexe, identifié les fragments minimaux des différentes protéines permettant de former ce complexe et mis au point un protocole robuste de purification de ce complexe, j’ai pu obtenir des cristaux de ce complexe dans plusieurs conditions. Par la suite, nous avons pu résoudre la structure de ce complexe par remplacement moléculaire avec une résolution de 2 Å. Enfin, j'ai montré que les mutations dans les lamines de type A provoquant des syndromes de type progéroïde pouvaient altérer l'interaction avec BAF in vitro, et nos collaborateurs, l'équipe du Dr B. Buendia (Paris Diderot), ont montré que ces mêmes mutations induisaient une diminution significative de la proximité entre la lamine A et BAF dans les cellules HeLa. Un article, où je suis premier auteur, vient d’être soumis au journal NSMB.The nucleus is an organelle characteristic of eukaryotic cells and its mechanical properties play an essential role in the behavior of the cell, in particular its motility, polarity and survival. It is surrounded by an envelope comprising an inner membrane and an outer membrane, as well as a large number of proteins. These proteins are either anchored at the nuclear membrane, as emerin, or form a filament meshwork lining the inner nuclear membrane, as lamins. My thesis objectives were to understand molecular mechanisms deficient in two types of genetic diseases caused by mutations in inner nuclear envelope proteins: Emery-Dreifuss muscular dystrophy, associated to mutations in emerin and A-type lamins, and progeroid syndromes caused by mutations in A-type lamins.First, we showed that the emerin protein self-assembles in vitro and in cells (Herrada, Samson et al., ACS Chem. Biol., 2015). I then studied the structure of emerin oligomers, determined the minimal protein fragment necessary for the formation of these oligomers, identify residues forming the structural core of these oligomers by solid-state NMR in collaboration with the group of Prof A. Lange (FMP Berlin), and described the impact of emerin mutations causing Emery-Dreifuss muscular dystrophy on emerin self-assembly (Samson et al., Biomol. NMR Assign. 2016, Samson et al., FEBS J. 2017). Then, I observed, mainly using solution-state NMR, that only the self-assembled form of emerin is able to interact with A-type lamin tail, and that mutants causing Emery-Dreifuss muscular dystrophy and unable to self-assemble are also defective in A-type lamin binding. I also obtained preliminary data showing that phosphorylation of emerin by the Src kinase, observed after a mechanical stress in purified nuclei, regulates the interaction between self-assembled emerin and A-type lamins.Finally, I showed that the monomeric form of emerin is able to form a ternary complex with A-type lamin tail through the chromatin-associated protein Barrier-to-Autointegration Factor (BAF). After having measured the protein-protein affinities within this complex, identified the minimal protein fragments involved in the complex and developed a robust protocol for purification of this complex, I was able to obtain crystals under several conditions. Subsequently, I solved the 3D structure of this complex by molecular replacement at a resolution of 2 Å. Finally, I showed that mutations in A-type lamins causing autosomal recessive progeroid syndromes impair interaction with BAF in vitro, and our collaborators at Univ. Paris Diderot, the team of Dr B. Buendia, showed that these same mutations induce a significant decrease in the proximity between lamin A and BAF in HeLa cells. An article with me as a first author is in preparation that reports all these new data